<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2806222271
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2022
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ASACOL
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        MESALAZINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        1600
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        modified-release tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        295.55
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Haupt Pharma Wulfing GmbH" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Haupt Pharma Wulfing GmbH
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 606]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ALHAYA MEDICAL CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Tillotts Pharma GmbH
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A07EC02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Asacol contains the active substance mesalazine. This is an anti-inflammatory medicine used to treat ulcerative colitis and Crohn&rsquo;s ileo-colitis. Ulcerative colitis is a disease in which the lining of the large bowel (colon) or back passage (rectum), in which the lining of the bowel becomes inflamed (red and swollen). Asacol treats and prevents inflammation throughout the entire colon and rectum (mild to moderate acute ulcerative colitis and for the prevention of relapse).</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Asacol</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to mesalazine or any of the other ingredients of this medicine (listed in section 6).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to salicylates (e.g. acetylsalicylic acid)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have severe liver problems</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have severe kidney problems</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or pharmacist before using Asacol if you have any medical conditions or illnesses, particularly if you have:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; any lung disease problems, e.g. asthma.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; impaired function of kidneys or lungs, especially if you are elderly.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; suffered an allergy to sulphasalazine in the past.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; had an allergic reaction of your heart such as inflammation of the heart muscle or heart sac. If you have had previous suspected mesalazine-induced allergic reactions of your heart, then Asacol must not be used. Asacol can be used with care if you have had a previous allergic reaction of the heart not caused by mesalazine.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have ever developed a severe skin rash or skin peeling, blistering and/or mouth sores after using mesalazine.</p><p>&nbsp;</p><p>Serious skin reactions including Drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported in association with mesalazine treatment. Stop using mesalazine and seek medical attention immediately if you notice any of the symptoms related to these serious skin reactions described in section 4.</p><p>&nbsp;</p><p>If you have a stomach ulcer, you should use Asacol with care.</p><p>&nbsp;</p><p>Kidney stones may develop with use of mesalazine. Symptoms may include pain in sides of abdomen and blood in urine. Take care to drink sufficient amount of liquid during treatment with mesalazine.</p><p>&nbsp;</p><p>Mesalazine may produce red-brown urine discoloration after contact with sodium hypochlorite bleach in the toilet water. It concerns a chemical reaction between mesalazine and bleach and is harmless.</p><p>&nbsp;</p><p><strong>Test for your liver, kidney and blood</strong></p><p>Before and while you are taking Asacol, your doctor may want to check that your liver, kidneys, blood and lungs are working properly.</p><p><strong>&nbsp;</strong></p><p><strong>Children and adolescents</strong></p><p>Do not give this medicine to children or adolescents under the age of 18 years of age, because Asacol has not been tested in this age group.</p><p>&nbsp;</p><p><strong>Other medicines and Asacol</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines such as:</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines that prevent the formation of blood clots (anticoagulants, e.g. warfarin). The effect of these medicines could be increased or decreased, the effect this may have on you is unclear.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines affecting the immune system (e.g. azathioprine, 6-mercaptopurine or thioguanine). Used together with Asacol, these medicines may lead to life-threatening infections (see Section 4).</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Non-steroidal anti-inflammatory drugs (for example: medicines containing acetylsalicylic acid, ibuprofen or diclofenac)</p><p>&nbsp;</p><p><strong>Asacol with food and drink</strong></p><p>Please refer to section 3.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Since mesalazine is excreted in breast milk in small quantities, due care should be taken if using Asacol whilst breast-feeding. If the infant develops diarrhoea, breastfeeding should be discontinued.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Asacol has no or negligible influence on the ability to drive and use machines. However, if you are affected in any way you should not drive or operate machinery.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always use Asacol exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p>The tablets must be swallowed whole preferably with a glass of water. Do not chew, crush or break the tablets before swallowing. This is important for these tablets with modified release, if the tablets are not swallowed whole, they may not work as intended.</p><p>Asacol can be taken with or without food.</p><p>Your doctor will decide which dose you should take.</p><p>&nbsp;</p><p><em>The recommended dose is:</em></p><p><em>Adults</em></p><p><em>Active phase of disease:</em> When the disease is getting worse, the dose can be increased up to 4800 mg (three tablets) daily taken once daily <em>or</em> as one tablet 2 to 3 times a day.</p><p><em>Maintenance treatment:</em> 1600 mg taken daily.</p><p>&nbsp;</p><p>If you take more Asacol than you should</p><p>If you take more Asacol than you should, or if children have been taking medicine by accident, please contact your doctor, the nearest hospital or pharmacy to get an opinion of the risk and advice on action to be taken. Take the box with you, if possible.</p><p>&nbsp;</p><p>If you forget to take Asacol</p><p>If you forget to take a dose at the right time, just take the next dose as normal. Do not take a double dose to make up for a forgotten dose.</p><p>If you stop using Asacol</p><p>Use Asacol for as long as your doctor prescribed it to you. Talk to your doctor before changing or stopping the treatment.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong>Stop taking Asacol immediately and seek urgent medical advice if you notice any of the following symptoms: </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reddish non-elevated, target-like or circular patches on the trunk, often with central blisters, skin peeling, ulcers of mouth, throat, nose, genitals and eyes, widespread rash, fever and enlarged lymph nodes. These serious skin rashes can be preceded by fever and flu-like symptoms;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; develop unexplained bruising (without injury), bleeding under your skin, purple spots or patches under your skin, anaemia (feeling tired, weak and looking pale, especially on lips and nails and inside of eyelids), fever (high temperature), sore throat or unusual bleeding (e.g. nose bleeds).</p><p>&nbsp;</p><p>Asacol can in very rare cases affect the white blood cells so, in those cases, your immune system could get worse. If you get an infection with symptoms such as fever with serious worsening of your general condition, or fever with local symptoms of infection such as sore throat/pharynx/ mouth or urinary problems you should immediately see your doctor. Blood tests can then be taken to check for lack of white blood cells (agranulocytosis). It is important that you inform your doctor about all of your medications.</p><p>&nbsp;</p><p><strong><em>Other side effects: </em></strong></p><p>&nbsp;</p><p><strong>Common: <em>may affect up to 1 in 10 people</em></strong></p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; indigestion</p><p>&nbsp;</p><p><strong>Uncommon: <em>may affect up to 1 in 100 people</em></strong></p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high number of white blood cells called eosinophil granulocytes</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sensation of tingling, pricking and numbness</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itching skin, hives,</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chest pain</p><p>&nbsp;</p><p><strong>Rare: <em>may affect up to 1 in 1,000 people</em></strong></p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the heart with signs like chest pains or palpitations</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea, stomach pain, wind (flatulence), feeling of unease and discomfort in the stomach with an urge to vomit and vomiting.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased sensitivity of your skin to sun and ultraviolet light (photosensitivity).</p><p><strong>&nbsp;</strong></p><p><strong>Very rare : <em>may affect up to 1 in 10,000 people</em></strong></p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe reduction in blood cells which can cause weakness, bruising or make infections more likely, low blood cell counts; reduction in blood platelets which increases the risk of bleeding</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allergic reactions such as rash</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever that occurs while taking the medicine and which disappears when the medicine is stopped (drug fever)</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; immune system disease that can involve organs and joints</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ulcerative colitis involving the entire large intestine</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal or damaged nerves giving a sensation of numbness or tingling</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lung disease (scarring of lung tissue, allergic reaction) resulting in difficulty in breathing, cough, wheezing and collection of fluid in the lungs, pneumonia</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflamed pancreas (associated with pain in upper abdomen and back and feeling sick)</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal liver function tests, hepatitis (inflammation of the liver giving rise to flu-like symptoms and jaundice)</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hair loss</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle or joint pain</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; kidney problems (such as inflammation and scarring of the kidney), kidney failure, which may be reversible if treatment is stopped early</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reversible decrease in sperm production.</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>Not known: <em>frequency cannot be estimated from the available data</em></strong></p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; disorder of the immune system (lupus-like syndrome) which can cause inflammation of the heart sac or membranes around the lungs and heart, rash and /or joint pain</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; kidney stones and associated kidney pain (see also section 2)inflammation of the membranes of the pleural cavity surrounding the lungs (pleurisy)</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weight loss</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; laboratory test results out of normal range.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not store above 30&deg;C</p><p>Keep this medicine out of the sight and reach of children.</p><p>Do not take this medicine after the expiry date which is stated on the carton and the blister strips. The expiry date refers to the last day of that month.</p><p>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is mesalazine. One tablet contains 1600 mg mesalazine.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are:</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; magnesium stearateE 470B</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; methacrylic acid-methyl methacrylate copolymer (1:2)</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; triethylcitrate</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; iron oxide yellow (E 172)</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; iron oxide red (E 172)</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; macrogol</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; microcrystalline cellulose</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; glycerol monostearate 40-55</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hypromellose</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; maize starch</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; polysorbate 80</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; potassium dihydrogen phosphate</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; colloidal anhydrous silica</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sodium starch glycolate (type A).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Asacol 1600 mg modified-release tablets are reddish brown in colour. The tablets are oblong shaped and approximately 2.3 cm in length, 1.1 cm in width and 0.9 cm in thickness.
Tablets are available in packs in blister strips. The blister strips are packed in a carton containing 60 tablets.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><u>The marketing authorisation holder is:</u></p><p>Tillotts Pharma GmbH</p><p>Warmbacher Str. 80</p><p>79618 Rheinfelden</p><p>Germany</p><p>&nbsp;</p><p><u>The manufacturer is:</u></p><p>Haupt Pharma W&uuml;lfing GmbH</p><p>Bethelner Landstrasse 18</p><p>&nbsp;D &ndash; 31028 Gronau</p><p>Germany</p><p>&nbsp;</p><p><strong>To report any side effect(s):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia:</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance Centre (NPC)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC states: </strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Please contact the relevant competent authority</em></p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Council of Arab Health Ministers</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:614px"><tbody><tr><td style="vertical-align:top"><p><strong><em>This is a Medicament</em></strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Medicament is a product which affects your health and its consumption contrary to instructions is dangerous for you.</em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Follow strictly the doctor&rsquo;s prescription, the method of use and the instructions of the pharmacist who sold the medicament. </em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>The doctor and the pharmacist are the experts in medicines, their benefits and risks. </em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Do not by yourself interrupt the period of treatment prescribed for you. </em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Do not repeat the same prescription without consulting your doctor.</em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Keep all medicaments out of reach of children.</em></p></td></tr></tbody></table><p>Council of Arab Health Ministers</p><p>Union of Arab Pharmacists</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This patient information leaflet was last revised in November 2022.


            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي أساكول على المادة النشطة ميسالازين. وهو دواء مُضاد للالتهاب يُستخدم لعلاج التهاب القولون التقرحي. التهاب القولون التقرحي هو مرض تصبح فيه بطانة الأمعاء الغليظة (القولون) أو المؤخرة (المستقيم) مُلتهبة (أي تحمّر وتتورّم). وقد يؤدي هذا إلى التبرز بشكل متكرر وإلى إخراج براز دموي عادة ما يكون مصحوب بتشنجات بطنية.</p><p dir="RTL">يُعالج أساكول الالتهاب ويمنعه في جميع أنحاء القولون والمستقيم (التهاب القولون التقرحي الخفيف إلى المتوسط ولمنع الانتكاس).</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>موانع استخدام أساكول:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك حساسية للميسالازين أو لأي من المُكونات الأخرى لهذا الدواء (مُدرجة في القسم رقم 6).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك حساسية للساليسيلات (مثل حمض الأسيتيل ساليسيليك)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشاكل حادة في الكبد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشاكل حادة في الكلى</p><p>&nbsp;</p><p dir="RTL"><strong>الاحتياطات عند استخدام أساكول</strong></p><p dir="RTL">تحدث مع طبيبك أو مع الصيدلي قبل استعمال أساكول إذا كنت تعاني من أي حالات طبية أو أمراض، وخاصة إذا كنت تعاني من:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أي مشاكل في الرئتين، مثل الربو</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اعتلال في وظائف الكلى أو الرئتين، وخاصة إذا كنت كبيراً في السن.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا عانيت في الماضي من حساسية للسلفاسالازين.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا عانيت من رد فعل تحسسي في قلبك مثل التهاب عضلة القلب أو كيس القلب. إذا عانيت سابقاً من ردود فعل تحسسية في قلبك اشتبه بأنها ناجمة عن الحساسية للميسالازين، فعندها ينبغي عدم استعمال أساكول. يمكن استعمال أساكول بعناية إذا كنت قد تعرضت سابقاً لرد فعل تحسسي في القلب لم يكن ناجماً عن الميسالازين.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد أصبت في أي وقت مضى بطفح جلدي شديد أو تقشر جلدي ، تقرحات و / أو تقرحات في الفم بعد استخدام الميسالازين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تم الإبلاغ عن تفاعلات جلدية خطيرة بما في ذلك تفاعل دوائي مع فرط الحمضات والأعراض الجهازية (DRESS) ومتلازمة ستيفنز جونسون (SJS) وانحلال البشرة السمي (TEN) بالاقتران مع العلاج بالميسالازين. توقف عن استخدام الميسالازين واطلب العناية الطبية فورًا إذا لاحظت أيًا من الأعراض المرتبطة بتفاعلات الجلد الخطيرة الموضحة في القسم 4.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان لديك تقرح في المعدة، ينبغي عليك توخي الحذر عند استعمال أساكول.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يؤدي استخدام الميسالازين إلى تشكل حُصيّات الكلى. وقد تشمل الأعراض ألماً في الخاصرتين ووجود دم في البول. احرص على شرب كمية كافية من السوائل أثناء العلاج بالميسالازين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يتسبب الميسالازين في تغير لون البول إلى اللون الأحمر البني بعد التلامس مع مبيض هيبوكلوريت الصوديوم في ماء المرحاض. يتعلق بتفاعل كيميائي بين الميسالازين والمبيض وهو غير ضار.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>فحص الكبد والكلى والدم</strong></p><p dir="RTL">قبل وأثناء تناولك لأساكول، قد يرغب طبيبك بالتأكد من عمل كبدك وكليتيك ودمك ورئتيك بصورة صحيحة.</p><p>&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">ينبغي عدم إعطاء هذا الدواء للأطفال أو المراهقين دون سن 18 سنة لأنه لم يتم بعد فحص أساكول على هذه الفئة العمرية.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>التداخلات الدوائية من تناول أساكول مع أدوية أخرى أو أعشاب أو مكملات</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول حالياً أو إذا تناولت مؤخراً أو قد تتناول أي أدوية أخرى مثل:</p><p dir="RTL">- &nbsp;الأدوية التي تمنع تشكل جلطات الدم (مُضادات التخثر مثل وارافين). فمفعول هذه الأدوية قد يزداد أو يقل، وأثر ذلك عليك غير واضح.</p><p dir="RTL">- &nbsp;الأدوية التي تؤثر على الجهاز المناعي (مثل أزاثيوبرين، 6-مركابتوبورين أو ثيوغوانين). فاستعمال هذه الأدوية مع أساكول قد يؤدي إلى عدوات تهدد الحياة (أنظر القسم رقم 4).</p><p dir="RTL">- &nbsp;الأدوية غير الستيرويدية المضادة للالتهابات (مثل: الأدوية التي تحتوي على حمض الأسيتيل ساليسيليك، إبوبروفين أو ديكلوفيناك)&nbsp;</p><p>&nbsp;</p><p dir="RTL"><strong>تناول أساكول مع الطعام والشراب</strong></p><p dir="RTL">يُرجى الرجوع للقسم رقم 3.</p><p>&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL">إذا كنتِ إمرأة حامل أو مُرضعة، أو إذا كنتِ تعتقدين أنكِ حامل أو تخططين للإنجاب، استشيري طبيبك أو الصيدلي قبل أخذ هذا الدواء. نظراً لإفراز الميسالازين في حليب الثدي بكميات صغيرة، ينبغي توخي الحذر عند استعمال أساكول أثناء فترة الرضاعة. في حال إصابة الطفل بالإسهال، ينبغي إيقاف الرضاعة.</p><p>&nbsp;</p><p dir="RTL"><strong>تأثير أساكول على القيادة واستخدام الآلات</strong></p><p dir="RTL">لا يوجد لأساكول أثر أو له أثر ضئيل على القدرة على قيادة السيارات واستعمال الآلات. ولكن، في حال تأثرت بأي شكل من الأشكال ينبغي عليك عدم القيادة أو تشغيل الآلات.</p><p><strong>&nbsp;</strong></p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">استعمل دوماً هذا الدواء تماماً حسب إرشادات طبيبك. استشر طبيبك أو الصيدلي إن كنت غير متأكد.</p><p>&nbsp;</p><p dir="RTL">ينبغي بلع الأقراص كاملة ويفضل بلعها مع كوب من الماء. لا تمضع الأقراص ولا تسحقها أو تكسرها قبل بلعها. وهذا مهم لأن هذه الأقراص مُعدّلة التحرر، وفي حال عدم بلعها كاملة فقد لا تعمل على النحو المنشود.</p><p>&nbsp;</p><p dir="RTL">يمكن تناول أساكول مع الطعام أو بدونه.</p><p>&nbsp;</p><p dir="RTL">سيقرر طبيبك الجرعة التي ينبغي عليك أخذها.</p><p>&nbsp;</p><p dir="RTL"><strong><em>الجرعة المُوصى بها هي:</em></strong></p><p dir="RTL"><strong><em>البالغون</em></strong></p><p dir="RTL"><em>المرحلة النشطة من المرض</em>: عندما تسوء حالة المرض، يمكن رفع الجرعة لغاية 4800 ملغ (ثلاثة أقراص) يومياً تؤخذ مرة واحدة في اليوم <em>أو</em> على على شكل قرص واحد من مرتين إلى ثلاثة مرات في اليوم.</p><p dir="RTL"><em>العلاج المستمر</em>: 1600 ملغ تؤخذ يومياً.</p><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL"><strong>في حال تناولك لكمية أكبر من اللازم من أساكول</strong></p><p dir="RTL">في حال تناولت كمية أكبر من اللازم من أساكول، أو في حال تناول أحد الأطفال الدواء عن طريق الخطأ، يُرجى الاتصال بطبيبك، أو بأقرب مستشفى أو بالصيدلية للحصول على رأيهم حول المخاطر والنصائح حول الإجراءات الواجب اتخاذها. وخذ العلبة معك، إن أمكن.</p><p>&nbsp;</p><p dir="RTL"><strong>في حال نسيانك لأخذ أساكول</strong></p><p dir="RTL">في حال نسيانك لأخذ جرعة في الوقت المناسب، فقط خذ الجرعة التالية كالمعتاد. لا تأخذ جرعة مزدوجة للتعويض عن الجرعة المنسية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حال توقفك عن استعمال أساكول</strong></p><p dir="RTL">استعمل أساكول للفترة التي وصفها لك طبيبك. وتحدث مع طبيبك قبل تغيير العلاج أو إيقافه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك أية أسئلة أخرى حول استعمال هذا الدواء، استشر طبيبك أو الصيدلي.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال مع جميع الأدوية، قد يتسبب هذا الدواء ببعض الآثار الجانبية، ولكنها لا تصيب الجميع.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong><u>توقف عن تناول أساكول واطلب النصيحة الطبية الفورية إذا لاحظت أيًا من الأعراض التالية</u></strong><strong><u>:</u></strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بقع حمراء غير مرتفعة ،&nbsp;شبيهة بلوح التصويب&nbsp;أو دائرية على منطقة الجذع ، غالبًا يُصاحبها بثور مركزية ، وتقشير الجلد ، وتقرحات في الفم ، والحلق ، والأنف ، والأعضاء التناسلية والعينين ، وطفح جلدي منتشر ، وحمى ، وتضخم في الغدد الليمفاوية. يمكن أن يُسبق هذا الطفح الجلدي الشديد بحمى وأعراض تشبه أعراض الأنفلونزا</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أصبت بكدمات لا تفسير لها (دون إصابة)، نزيف أسفل البشرة، نقاط أو بقع بنفسجية أسفل البشرة، فقر دم (الشعور بالتعب والضعف والشحوب، خاصة على الشفاه والأظافر وداخل الجفون)، حمّى (درجة حرارة مرتفعة)، التهاب الحلق أو نزيف غير طبيعي (مثل نزيف الأنف).</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يؤثر أساكول في حالات نادرة جداً على خلايا الدم البيضاء، لذا، في تلك الحالات، قد تسوء حالة جهازك المناعي. في حال إصابتك بعدوى مع أعراض مثل الحمى مع تدهور حالتك العامة بشكل خطير، أو في حال إصابتك بالحمّى مع أعراض موضعية لعدوى مثل التهاب الحلق/البلعوم/الفم أو مشاكل بولية، ينبغي عليك مراجعة طبيبك على الفور. ويمكن عندها إجراء فحوصات للدم للتأكد من عدم وجود نقص في خلايا الدم البيضاء (ندرة المحببات). ومن الضروري أن تخبر طبيبك عن جميع الأدوية التي تتناولها.&nbsp;</p><p>&nbsp;</p><p dir="RTL"><strong><em>الآثار الجانبية الأخرى:</em></strong></p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>الشائعة: <em>قد تصيب لغاية شخص 1 من كل 10 أشخاص</em></strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عسر هضم</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير الشائعة: <em>قد تصيب لغاية شخص 1 من كل 100 شخص</em></strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدد مرتفع من خلايا الدم البيضاء تُسمى الخلايا الحبيبية الحمضية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إحساس بالوخز واللسع والخدران</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة البشرة، قشعريرة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الصدر</p><p>&nbsp;</p><p dir="RTL"><strong>النادرة: <em>قد تصيب لغاية شخص 1 من كل 1.000 شخص</em></strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوار</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب القلب مع علامات مثل ألم في الصدر أو خفقان القلب</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال، ألم المعدة، ريح (انتفاخ)، الشعور بالإزعاج وعدم الارتياح في المعدة مع رغبة في التقيوء، والتقيوء الفعلي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحسس زائد لبشرتك من الشمس والأشعة فوق البنفسجية (الحساسية الضوئية)</p><p>&nbsp;</p><p dir="RTL"><strong>النادرة جداً: <em>قد تصيب لغاية شخص 1 من كل 10.000 شخص</em></strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض حاد في خلايا الدم قد يتسبب بالضعف أو التكدم أو قد يزيد من احتمالية الإصابة بالالتهابات، انخفاض عدد خلايا الدم؛ انخفاض في عدد الصفائح الدموية يزيد من خطر النزيف</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ردود فعل تحسسية مثل الطفح الجلدي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمّى تحدث أثناء تناول الدواء وتختفي عند إيقاف الدواء (حمى الدواء)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض في الجهاز المناعي قد يصيب الأعضاء والمفاصل</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب القولون التقرحي يشمل كامل الأمعاء الغليظة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اعتلال أو تضرر الأعصاب يؤدي إلى الشعور بالخدران أو الوخز</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض الرئة (تندب أنسجة الرئة، رد فعل تحسسي) يؤدي إلى صعوبة في التنفس أو الصفير وإلى تجمع السوائل في الرئتين، الالتهاب الرئوي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب البنكرياس (يصاحبه ألم في الجزء العلوي من المعدة والظهر والشعور بالمرض)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نتائج غير طبيعية لفحوصات وظائف الكبد، التهاب الكبد الوبائي (التهاب للكبد يؤدي إلى ظهور أعراض شبيهة بأعراض الانفلونزا واليرقان)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشعر</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في العضلات أو المفاصل</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في الكلى (مثل التهاب الكلى وتندبها)، فشل كلوي، قد يكون قابل للعكس في حال إيقاف العلاج في وقت مُبكر</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عكسي في إنتاج الحيوانات المنوية.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>غير المعروفة: <em>لا يمكن تقدير نسبة تكرارها من البيانات المتوفرة</em></strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب في الجهاز المناعي (متلازمة شبيهة بالذئبة) قد يتسبب بالتهاب كيس القلب أو الأغشية حول الرئتين والقلب، والطفح الجلدي و/أو ألم المفاصل</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حصوات الكلى وما يصاحبها من آلام في الكلى (انظر أيضًا القسم 2) التهاب أغشية التجويف الجنبي المحيط بالرئتين (ذات الجنب)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الوزن</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خروج نتائج الفحوصات المخبرية عن معدلاتها الطبيعية</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">لا تخزّن الدواء في درجة حرارة فوق 30 مئوية.</p><p dir="RTL">يُحفظ هذا الدواء بعيداً عن مرأى وعن متناول الأطفال.</p><p dir="RTL">لا تتناول هذا الدواء بعد انتهاء تاريخ الصلاحية المذكور على العلبة وعلى أشرطة الدواء. يشير انتهاء تاريخ الصلاحية إلى آخر يوم من الشهر المذكور.</p><p>&nbsp;</p><p dir="RTL">ينبغي عدم التخلص من الأدوية من خلال مياه الصرف الصحي أو برميها في نفايات المنزل. اسأل الصيدلي حول كيفية التخلص من الأدوية التي لم تعد تستعملها. ستساعد هذه الإجراءات في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><em>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>المادة الفعالة هي ميسالازين. يحتوي القرص الواحد على 1600 ملغ ميسالازين.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مغنيسيوم ستيرات E 470B</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمض ميثاكريليك-بوليمر مشترك ميثيل ميثاكريلات (1:2)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تريإيثيلسترات</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أصفر أكسيد الحديد (E 172)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أحمر أكسيد الحديد (E 172)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ماكروغول</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ميكروكريستالين سيلولوز</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غليسيرول مونوستيارات 40-55</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هايبرميلوز</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نشا الذرة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بوليسوربات 80</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بوتاسيوم ديهايدروجن فوسفات</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيليكا غروانية لامائية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غليكولات نشا الصوديوم (النوع أ).</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">أقراص أساكول 1600 ملغ مُعدّلة التحرر لها لون بني مُحمر. الأقراص مستطيلة الشكل ويبلغ طولها 2.3 سم وعرضها 1.1 سم وسماكتها 0.9 سم تقريباً.</p><p dir="RTL">الأقراص متوفرة بعلب تحتوي على أشرطة. أشرطة الدواء مُعبأة في علبة كرتونية تحتوي على 60 قرص.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><u>مالك رخصة التسويق:</u></p><p dir="RTL">تيلوتس فارما جي ام بي اتش</p><p dir="RTL">وارمباكر شارع. 80</p><p dir="RTL">79618 راينفيلدن</p><p dir="RTL">ألمانيا</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الشركة المُصنّعة:</u></p><p dir="RTL">هاوبت فارما وولفينج جي إم بي إتش</p><p dir="RTL">بيتهيلنر لاندستراس 18</p><p dir="RTL">د - 31028 جروناو</p><p dir="RTL">ألمانيا</p><p>&nbsp;</p><p dir="RTL"><strong>للإبلاغ عن أي أثر جانبي/آثار جانبية:</strong></p><p><strong>&nbsp;</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong><em>المملكة العربية السعودية</em></strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">المركز الوطني للتيقظ الدوائي:</p><p dir="RTL">مركز االتصال الموحد: 19999</p><p dir="RTL">البريد الإلكتروني npc.drug@sfda.gov.sa :</p><p dir="RTL">الموقع الإلكتروني https://ade.sfda.gov.sa :</p></td></tr></tbody></table><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong><em>دول الخليج العربي الأخرى</em></strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="LTR">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُرجى الاتصال بالهيئة المختصة.</p><p dir="RTL">&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p dir="RTL">مجلس وزراء الصحة العرب</p><p dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:524px"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>إن هذا الدواء</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدواء مستحضر يؤثر على صحتك واستهلاكه خلافا للتعليمات يعرضك للخطر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اتبع بدقة وصفة الطبيب وطريقة الاستعمال المنصوص عليها، وتعليمات الصيدلي الذي صرفها لك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطبيب والصيدلي هما الخبيران في الدواء، وفي نفعه وضرره.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تقطع مدة العلاج المحددة لك من تلقاء نفسك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تكرر صرف الدواء بدون استشارة الطبيب المختص.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تترك الأدوية في متناول الأطفال.</p><p dir="LTR">&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL">مجلس وزراء صحة العرب</p><p dir="RTL">اتحاد الصيادلة العرب</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة نشرة معلومات المريض هذه في نوفمبر 2022.


        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Asacol 1600 mg modified-release tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each modified-release tablet contains: 1600 mg mesalazine.

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Modified-release tablet.

Film-coated, red/brown oblong tablets dimension of 23 x 11 x 9 mm.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Ulcerative colitis.</em></p><p>&nbsp;</p><p>For the treatment of mild to moderate acute disease. For the maintenance of remission.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p><u>&nbsp;</u></p><p><u>Adults, including the elderly (&gt;65 years)</u></p><p>&nbsp;</p><p>The dose should be adjusted according to the severity of the disease and tolerance.</p><p><u>&nbsp;</u></p><p><em>Acute disease</em>: In the event of exacerbation, the dose can be increased to 4800 mg daily, once daily or in 2-3 divided doses.</p><p>Once clinical remission is achieved, the dose should gradually be decreased to maintenance dose.</p><p>&nbsp;</p><p>Continued therapy should be carefully considered in subjects not responding by week 8.</p><p>&nbsp;</p><p><em>Maintenance treatment</em>: 1600 mg once daily.</p><p><em>&nbsp;</em></p><p>Other oral mesalazine formulations are available if an alternative dose for maintenance treatment is considered more appropriate.</p><p><em>&nbsp;</em></p><p><u>Elderly population</u></p><p>No studies have been carried out in older people.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>The safety and efficacy of Asacol in children and adolescents aged younger than 18 years of age has not been established.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Method of administration</u>: oral.</p><p>The tablets must be swallowed whole with a glass of water. They must not be chewed, crushed or broken before swallowing. The tablets can be taken with or without food. If one or more doses have been missed, the next dose is to be taken as usual.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •	Hypersensitivity to salicylates (including mesalazine) or any of the excipients listed in section 6.1.
•	Severe liver impairment.
•	Severe renal impairment (GFR < 30 mL/min/1.73 m2).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Blood tests (differential blood count; liver function parameters such as ALT or AST; serum creatinine) and urinary status (dip-sticks) should be determined prior to and during treatment, at the discretion of the treating physician. As a guideline, follow-up tests are recommended 14 days after commencement of treatment, then a further two to three tests at intervals of 4 weeks.</p><p>If the findings are normal, follow-up tests should be carried out every 3 months. If additional symptoms occur, these tests should be performed immediately.</p><p><u>Renal impairment</u><br />Asacol should not be used in patients with renal impairment. Asacol-induced renal toxicity shall be suspected if the renal function is impaired during the treatment and the treatment should be stopped immediately.</p><p>It is recommended that the renal function is monitored prior to and repeatedly whilst on Asacol therapy.</p><p><u>Nephrolithiasis</u><br />Cases of nephrolithiasis have been reported with the use of mesalazine including stones with a 100% mesalazine content. It is recommended to ensure adequate fluid intake during treatment.</p><p>Mesalazine may produce red-brown urine discoloration after contact with sodium hypochlorite bleach (e.g., in toilets cleaned with sodium hypochlorite contained in certain bleaches).</p><p><u>&nbsp;</u></p><p><u>Severe cutaneous adverse reactions</u></p><p>Severe cutaneous adverse reactions (SCARs), including Drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have been reported in association with mesalazine treatment.</p><p>Mesalazine should be discontinued, at the first appearance of signs and symptoms of severe skin reactions, such as skin rash, mucosal lesions, or any other sign of hypersensitivity.</p><p>&nbsp;</p><p>Mesalazine should be discontinued, at the first appearance of signs and symptoms of severe skin reactions, such as skin rash, mucosal lesions, or any other sign of hypersensitivity.</p><p><u>&nbsp;</u></p><p><u>Blood dyscrasia</u></p><p>Very rarely have serious blood dyscrasia been reported. Asacol therapy should be stopped <u>immediately</u> if there is a suspicion or evidence of blood dyscrasia (signs of unexplained bleeding, bruising, purpura, anaemia, persistent fever or sore throat), and the patient should seek immediate medical advice.</p><p>&nbsp;</p><p><u>Liver impairment</u></p><p>There have been reports of increased liver enzyme levels in patients taking preparations containing Asacol. Caution is recommended if Asacol is administered to patients with liver impairment.</p><p>&nbsp;</p><p><u>Cardiac hypersensitivity reactions</u></p><p>Asacol-induced hypersensitivity reactions (myo- and pericarditis) have been reported rarely with Asacol. In case of a suspected cardiac hypersensitivity, Asacol must not be reintroduced. Caution should be taken in patients with previous myo- or pericarditis of allergic background regardless of its origin.</p><p>&nbsp;</p><p><u>Pulmonary disease</u></p><p>Patients with pulmonary disease, in particular asthma, should be very carefully monitored during treatment with Asacol.</p><p>&nbsp;</p><p><u>Hypersensitivity to sulphasalazine</u></p><p>Patients with a history of adverse drug reactions to sulphasalazine, therapy should be kept under close medical supervision. Treatment must be stopped <u>immediately</u> if acute symptoms of intolerance occur such as abdominal cramps, acute abdominal pain, fever, severe headache and rash.</p><p>&nbsp;</p><p><u>Gastric and duodenal ulcers</u></p><p>Caution is recommended when treating patients with active gastric or duodenal ulcer.</p><p><u>&nbsp;</u></p><p><u>Elderly patients</u></p><p>Asacol should be administered with caution in elderly patients, it should only be given to patients with normal to moderate renal impairment (see section 4.3).</p><p><u>&nbsp;</u></p><p><u>Paediatric population</u></p><p>There is only limited documentation for an effect in children, see section 4.2.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No interaction studies have been performed.</p><p>&nbsp;</p><p>There is evidence that mesalazine might decrease the anticoagulant effect of warfarin.</p><p>&nbsp;</p><p>Caution is recommended for the concomitant use of mesalazine with known nephrotoxic agents, including non-steroidal anti-inflammatory drugs (NSAIDs) and azathioprine, or methothrexate as these may increase the risk of renal adverse reactions.</p><p>&nbsp;</p><p>A possible increase in the myelosuppressive effects of azathioprine, 6-mercaptopurine or thioguanine in patients who are concomitantly treated with any of these preparations, should be taken into account. Life-threatening infection can occur. Patients should be closely observed for signs of infection and myelosuppression. Haematological parameters, especially the leukocyte, thrombocyte and lymphocyte cell counts should be monitored regularly (weekly), especially at initiation of such combination therapy, see section 4.4.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>There are no adequate data on the use of Asacol in pregnant women. However, data on a limited number of exposed pregnancies indicate no adverse effect of mesalazine on pregnancy or on the foetus/newborn child. To date, no other relevant epidemiologic data are available.</p><p>&nbsp;</p><p>In one single case after long-term use of a high dose of mesalazine (2-4 g, orally) during pregnancy, renal failure in a neonate was reported.</p><p>&nbsp;</p><p>Animal studies on oral mesalazine do not indicate direct or indirect harmful effects with respect to pregnancy, embryonic/foetal development, parturition or postnatal development. Asacol should only be used during pregnancy if the potential benefit outweighs the possible risk.</p><p>&nbsp;</p><p><u>Breastfeeding</u></p><p>N-acetyl-5-aminosalicylic acid and to a lesser degree mesalazine are excreted in breast milk. The clinical significance of this has not been determined. Only limited experience during lactation in women is available to date. Hypersensitivity reactions such as diarrhoea in the infant cannot be excluded. Therefore, Asacol should only be used during breast-feeding if the potential benefit outweighs the possible risk. If the infant develops diarrhoea, breast-feeding should be discontinued.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>No effects on fertility have been observed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed. Asacol is considered to have negligible influence on these abilities.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>a) Summary of the safety profile</em></p><p>Organ specific adverse drug reactions affecting the heart, lungs, liver, kidneys, pancreas, skin and subcutaneous tissue have been reported. Headache (1.7%), haematuria (1.7%), abdominal pain (1.5%), ulcerative colitis (1.5%) and proteinuria (1.5%) are the most commonly reported drug related adverse events in the clinical development programme.</p><p>&nbsp;</p><p>Treatment must be stopped immediately if acute symptoms of intolerance occur such as abdominal cramps, acute abdominal pain, fever, severe headache and rash.</p><p>&nbsp;</p><p>Severe cutaneous adverse reactions (SCARs), including Drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have been reported in association with mesalazine treatment (see section 4.4).</p><p>&nbsp;</p><p><em>b) Tabulated summary of adverse reactions</em></p><p>Undesirable effects reported from clinical studies and other sources are listed below:</p><p>&nbsp;</p><p>Common (&ge; 1/100 to &lt; 1/10), uncommon (&ge; 1/1,000 to &lt; 1/100), rare (&ge; 1/10,000 to &lt; 1/1,000), very rare (&lt; 1/10,000), not known (cannot be estimated from the available data).</p><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:998px"><thead><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p><p>(&sup3;&nbsp;1/100 to &lt;&nbsp;1/10)</p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p><p>(&sup3;&nbsp;1/1,000 to &lt;&nbsp;1/100)</p></td><td style="vertical-align:top"><p><strong>Rare</strong></p><p>(&sup3;&nbsp;1/10,000 to &lt;&nbsp;1/1,000)</p></td><td style="vertical-align:top"><p><strong>Very Rare</strong></p><p>(&lt;&nbsp;1/10,000)</p></td><td style="vertical-align:top"><p><strong>Not known</strong></p><p>(Cannot be estimated from the available data)</p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><strong>Blood and Lymphatic System Disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Eosinophilia (as part of an allergic reaction).</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Altered blood counts (aplastic anemia, agranulocytosis, pancytopenia, neutropenia, leukopenia, thrombocytopenia), blood dyscrasia.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune System Disorders</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypersensitivity reactions such as allergic exanthema, drug fever, lupus erythematosus syndrome, pancolitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous System Disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Paresthesia</p></td><td style="vertical-align:top"><p>Headache, dizziness</p></td><td style="vertical-align:top"><p>Peripheral neuropathy</p></td><td style="vertical-align:top"><p><sup>&nbsp;</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac Disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Myocarditis, pericarditis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Allergic and fibrotic lung reactions (including dyspnoea, cough, bronchospasm, alveolitis, pulmonary eosinophilia, lung infiltration, pneumonitis), interstitial pneumonia, eosinophilic pneumonia, lung disorder.</p></td><td style="vertical-align:top"><p>Pleurisy</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal Disorders</strong></p></td><td style="vertical-align:top"><p>Dyspepsia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Abdominal pain, diarrhoea, flatulence, nausea, vomiting</p></td><td style="vertical-align:top"><p>Acute pancreatitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary Disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Changes in liver function parameters (increase in transaminases and cholestasis parameters), hepatitis, cholestatic hepatitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and Subcutaneous Tissue Disorders</strong></p></td><td style="vertical-align:top"><p>Rash</p></td><td style="vertical-align:top"><p>Urticaria, pruritus</p></td><td style="vertical-align:top"><p>Photosensitivity*</p></td><td style="vertical-align:top"><p>Alopecia</p></td><td style="vertical-align:top"><p>Drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal, connective tissue and bone disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Myalgia, arthralgia</p></td><td style="vertical-align:top"><p>Lupus-like syndrome with pericarditis and pleuropericarditis as prominent symptoms as well as rash and arthralgia</p></td></tr><tr><td style="vertical-align:top"><p><strong>Renal and Urinary Disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Impairment of renal function including acute and chronic interstitial nephritis and renal insufficiency, nephrotic syndrome, renal failure which may be reversible on early withdrawal.</p></td><td style="vertical-align:top"><p>Nephrolithiasis**</p></td></tr><tr><td style="vertical-align:top"><p><strong>Reproductive system and breast disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Oligospermia (reversible)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pyrexia, chest pain</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Intolerance to mesalazine with C-reactive protein increased and/or exacerbation of symptoms underlying disease</p></td></tr><tr><td style="vertical-align:top"><p><strong>Investigations</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Blood creatinine increased, weight decreased, creatinine clearance decreased, amylase increased, red blood cell sedimentation rate increased, lipase increased, BUN increased.</p></td></tr></tbody></table><p>* see section c)</p><p>** See section 4.4 for further information</p><p>&nbsp;</p><p>&nbsp;</p><p><em>c) Description of selected adverse reactions</em></p><p>An unknown number of the above-mentioned undesirable effects are probably associated to the underlying IBD rather than Asacol medication. This holds true especially for gastrointestinal undesirable effects, arthralgia, and alopecia.</p><p>&nbsp;</p><p>To avoid blood dyscrasia resulting from developing bone marrow depression patients should be monitored with care, see section 4.4.</p><p>&nbsp;</p><p>Under co-administration of mesalazine with immunosuppressive drugs such as azathioprine, 6-MP or thioguanine, life-threatening infection can occur, see section 4.5.</p><p>&nbsp;</p><p><em>Photosensitivity</em></p><p>More severe reactions are reported in patients with pre-existing skin conditions such as atopic dermatitis and atopic eczema.</p><p>&nbsp;</p><p><em>d) Paediatric population</em></p><p>There is no safety experience with the use of Asacol tablets in the paediatric population. It is expected that the target organs of possible adverse reactions in the paediatric population are the same as for adults (heart, lungs, liver, kidneys, pancreas, skin and subcutaneous tissue).</p><p><strong>&nbsp;</strong></p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the following route:</p><p><strong>To report any side effect(s): </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong><em>Saudi Arabia: </em></strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p><p>The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/</p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong><em>Other GCC States: </em></strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Please contact the relevant competent authority. </em></p><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Mesalazine is an aminosalicylate, and signs of salicylate toxicity include tinnitus, vertigo, headache, confusion, drowsiness, pulmonary oedema, dehydration as a result of sweating, diarrhoea and vomiting, hypoglycaemia, hyperventilation, disruption of electrolyte balance and blood-pH and hyperthermia.</p><p>Conventional therapy for salicylate toxicity may be beneficial in the event of acute overdosage. Hypoglycaemia, fluid and electrolyte imbalance should be corrected by the administration of appropriate therapy. Adequate renal function should be maintained.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Intestinal anti-inflammatory agents, ATC code: A07EC02.</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>Asacol contains mesalazine, also known as 5-aminosalicylic acid, which has a topical anti-inflammatory effect on the colonic mucosal cells through mechanisms that have not yet been fully clarified.</p><p>&nbsp;</p><p>Asacol has been shown to inhibit LTB4-stimulated migration of intestinal macrophages by restricting migration of macrophages to inflamed areas. The production of pro-inflammatory leukotrienes (LTB<sub>4 </sub>and 5-HETE) in macrophages of the intestinal wall is thereby inhibited. Asacol has been shown to activate PPAR-&gamma; receptors which counteract nuclear activation of intestinal inflammatory responses.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>The Asacol tablet contains a core of 1600 mg mesalazine covered by a multi-layer coating system. This system consists of a layer of methacrylic acid - methyl methacrylate copolymer (Eudragit&nbsp;S) combined with starch particles on top of a middle alkaline buffer layer (which accelerates drug release). The coating is designed to delay release of mesalazine until intestinal fluids reach a pH of 7. The starch can be digested by colonic bacteria which also provides a second trigger for release of mesalazine from the coated tablet. Systemic bioavailability/plasma concentrations of mesalazine therefore are of no relevance for therapeutic efficacy, but rather a criterion for safety.</p><p>&nbsp;</p><p>The risk of colorectal cancer (CRC) is slightly elevated in ulcerative colitis.</p><p>&nbsp;</p><p>The effects observed by mesalazine in experimental models and from patient biopsies supports that mesalazine prevents colitis-associated CRC through down regulation of both the inflammation-dependent and non-dependent inflammatory signalling pathways that are involved in the development of colitis-associated CRC. Data from meta-analyses with populations both in remission and relapsing, provide however, an inconsistent clinical information on risk-benefit of mesalazine in the carcinogenesis of ulcerative colitis.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p><em>Mild to moderate acute ulcerative colitis</em></p><p>This indication was investigated in a randomised, active-controlled, double-blind, multi-centre, non-inferiority induction trial study with 817 patients receiving 3.2g mesalazine daily for 8 weeks.</p><p>At week 8, 22.4% of the Per-Protocol patients treated with Asacol 1600mg modified-release tablets and 24.6% of those treated with mesalazine 400mg tablets achieved clinical and endoscopic remission. The unadjusted between group difference was 2.2% (95% confidence interval: - 8.1% up to 3.8%). Taking into account the predefined non-inferiority margin of &ndash; 10%, once daily Asacol 1600mg modified-release tablets were considered to be non-inferior to twice daily mesalazine 400mg tablets in inducing clinical and endoscopic remission.</p><p>A total of 10.3% of patients treated with Asacol 1600mg modified-release tablets and 9.8% of patients receiving mesalazine 400mg tablets reported treatment related adverse events. The incidence of serious adverse events (SAEs) in both treatment groups was 2.0% versus 1.7%.</p><p>&nbsp;</p><p><em>Maintenance </em></p><p>727 patients participated in an open label extension (OLE) of the induction study. A total of 243 patients who showed no response at week 8 entered an extended induction period of 8 weeks on a daily dose of 4.8g.</p><p>&nbsp;</p><p>The daily dose of Asacol in the maintenance phase was allocated depending on the 8 or 12 week induction results. Patients in clinical remission (202) received 1.6g/day whereas patients with a clinical response (274) received 3.2g/day. Initial non-responders at week 8 who responded after a further 8 weeks on 4.8 g Asacol per day (199), remained on 4.8g for another 22 weeks</p><p>&nbsp;</p><p>At week 38 70.3% (142/202) with 1.6 g/day maintained remission. Additional 33.9% (93/274) and 30.7% (61/199) of patients in the 3.2 g/day and 4.8 g/day dose groups, respectively achieved a later clinical remission.</p><p>&nbsp;</p><p>The incidence of SAEs in the maintenance OLE was low and independent of daily dose, with 5.0% (10/202), 4.4% (12/274) and 1.5% (3/199) of patients in the 1.6, 3.2 and 4.8 g/day dose groups affected.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Asacol tablets have a modified release of mesalazine starting only at pH above 7, i.e., within the terminal ileum and colon. Approximately 31% of an oral dose (fasted state) is absorbed based on urinary excretion data for 60 hours.</p><p>&nbsp;</p><p>A single dose of a Asacol 1600 mg modified -release tablets in healthy volunteers in the fasted state resulted in a 1.5-fold increase of mesalazine C<sub>max</sub> and a 1.5-fold increase of AUC compared to fed state.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>About 43% mesalazine and 78% N-acetyl mesalazine are bound to plasma proteins.</p><p>Approximately 75 % of the administered dose remains in the gut lumen and the mucosal tissue. The mean apparent volume of distribution (Vdw) was 12.1 L/kg. Low concentrations of mesalazine and N-acetyl mesalazine have been detected in human breast milk. The clinical significance of this has not been determined.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>Mesalazine is metabolised both by the intestinal mucosa and the liver to the inactive metabolite N-acetyl mesalazine. Based on urinary excretion data, the absorbed dose is excreted to &gt;95% as metabolites.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>The elimination of mesalazine is essentially urinary and faecal in the form of mesalazine and its N-acetyl metabolite. About 23% of the dose administered was recovered in the urine within 60 h after fed and 31% under fasted administration (single dose of 1600mg tablet) The median elimination half-life of mesalazine was 20 hours (range: 5 to 77 hours).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There are no pre-clinical data of relevance to the prescriber which are additional to those already included in other sections of this SmPC.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Magnesium stearate E470B</p><p>Methacrylic acid methyl methacrylate copolymer (1:2)</p><p>Triethylcitrate</p><p>Iron oxide yellow (E172)</p><p>Iron oxide red (E172)</p><p>Macrogol</p><p>Microcrystalline cellulose</p><p>Glycerol monostearate (40-55)</p><p>Hypromellose</p><p>Maize starch</p><p>Polysorbate 80</p><p>Potassium dihydrogen phosphate</p><p>Colloidal anhydrous silica</p><p>Sodium starch glycolate (type A)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&ordm;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>PVC/aluminium blister 30 tablets, 60 tablets or 90 tablets.<br />Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements for disposal.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tillotts Pharma GmbH
Warmbacher Str. 80
79618 Rheinfelden
Germany
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                November 2022 
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>